Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces Third Quarter 2011 Results
November 08, 2011 16:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Third Quarter 2011 Operating Results and Corporate Update
November 03, 2011 16:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Litigation
October 20, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
September 12, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira to Present at the Stifel Nicolaus Annual Healthcare Conference
September 01, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Acquires Worldwide Exclusive License to Novel RNAi Platform
August 25, 2011 08:15 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces Second Quarter 2011 Results
August 11, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 11, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Arbutus Biopharma Logo
Tekmira Announces Additional Clinical Trial of TKM-PLK1 with the U.S. National Cancer Institute
August 09, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, along with its...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Second Quarter 2011 Operating Results and Corporate Update
August 04, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Reports Expected Answer and Amended Counterclaim is Filed by Alnylam
June 29, 2011 08:30 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 29, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, reports that Alnylam...